Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

REPRISE: tolvaptan in advanced polycystic kidney disease.

Wyatt CM, Le Meur Y.

Kidney Int. 2018 Feb;93(2):292-295. doi: 10.1016/j.kint.2017.12.002. No abstract available. Erratum in: Kidney Int. 2018 Apr;93(4):1019.

PMID:
29389391
2.

An update on tolvaptan for autosomal dominant polycystic kidney disease.

Poch E, Rodas L, Blasco M, Molina A, Quintana L.

Drugs Today (Barc). 2018 Sep;54(9):519-533. doi: 10.1358/dot.2018.54.9.2776624. Review.

PMID:
30303493
3.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
4.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators.

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.

5.

Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?

Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D.

Pediatr Nephrol. 2018 Mar;33(3):395-408. doi: 10.1007/s00467-017-3672-x. Epub 2017 Apr 28. Review.

PMID:
28455745
6.

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.

J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5.

7.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
8.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

9.

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators.

Am J Kidney Dis. 2017 Feb;69(2):210-219. doi: 10.1053/j.ajkd.2016.08.028. Epub 2016 Nov 14.

10.

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Blair HA, Keating GM.

Drugs. 2015 Oct;75(15):1797-806. doi: 10.1007/s40265-015-0475-x. Review.

PMID:
26407729
11.

Review of tolvaptan for autosomal dominant polycystic kidney disease.

Baur BP, Meaney CJ.

Pharmacotherapy. 2014 Jun;34(6):605-16. doi: 10.1002/phar.1421. Epub 2014 Apr 7. Review.

PMID:
24706579
12.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.

Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

13.

Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.

Lee Y, Blount KL, Dai F, Thompson S, Scher JK, Bitterman S, Droher M, Herzog EL, Moeckel G, Karihaloo A, Dahl NK.

Clin Exp Nephrol. 2018 Aug;22(4):906-916. doi: 10.1007/s10157-018-1542-x. Epub 2018 Feb 16.

PMID:
29453607
14.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

15.

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S.

Clin Exp Nephrol. 2015 Oct;19(5):867-77. doi: 10.1007/s10157-015-1086-2. Epub 2015 Feb 7.

PMID:
25663351
16.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

17.

Tolvaptan in Later-Stage Polycystic Kidney Disease.

Pazmiño PA.

N Engl J Med. 2018 Feb 1;378(5):488-9. doi: 10.1056/NEJMc1716478. No abstract available.

PMID:
29394475
18.

Tolvaptan in Later-Stage Polycystic Kidney Disease.

De Tymowski C, Legrand M.

N Engl J Med. 2018 Feb 1;378(5):488. doi: 10.1056/NEJMc1716478. No abstract available.

PMID:
29394474
19.

Tolvaptan in Later-Stage Polycystic Kidney Disease.

Torres VE, Gansevoort RT, Czerwiec FS.

N Engl J Med. 2018 Feb 1;378(5):489-490. doi: 10.1056/NEJMc1716478. No abstract available.

PMID:
29385372
20.

Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD).

Makabe S, Mochizuki T, Mitobe M, Aoyama Y, Kataoka H, Tsuchiya K, Nitta K.

Clin Exp Nephrol. 2018 Oct;22(5):1079-1087. doi: 10.1007/s10157-018-1545-7. Epub 2018 Mar 5.

PMID:
29508162

Supplemental Content

Support Center